# US 10,501,520 B2 · B7-H5, a costimulatory polypeptide > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,501,520 B2 - Document ID: US10501520B2 - Status: Granted - Kind: B2 - Application number: 15/845,158 - Filed: 2017-12-18 - Published: 2018-09-06 - Granted: 2019-12-10 - Earliest claimed: 2004-06-24 - Assignees: Mayo Foundation for Medical Education and Research - Applicants: Mayo Foundation for Medical Education and Research - Inventors: Lieping Chen - Web page: https://patentgrep.com/patent/US10501520B2 ## CPC - C07K 14/70532: {B7 molecules, e.g. CD80, CD86} - A61P 37/00: Drugs for immunological or allergic disorders - C07K 16/18: against material from animals or humans - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2317/52: Constant or Fc region; Isotype - C07K 2319/70: containing domain for protein-protein interaction - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. ## Claims ### Claim 1 A composition comprising a fusion protein and a pharmaceutically acceptable carrier, wherein the fusion protein comprises: a first domain that consists of an amino acid sequence encoded by a nucleic acid sequence that encodes a protein consisting of an extracellular region of a protein, wherein the nucleic acid sequence hybridizes over its full length, after a wash at 50° C. to 60° C. in a buffer containing 0.2×SSC and 0.1% SDS, to the complement of a nucleotide sequence consisting of nucleotide 88 to nucleotide 936 of SEQ ID NO:2; and at least one additional domain comprising an amino acid sequence that is unrelated to SEQ ID NO:1. ### Claim 2 (depends on 1) The composition of claim 1, wherein the at least one additional domain is all or part of an immunoglobulin heavy chain constant region. ### Claim 3 (depends on 1) The composition of claim 1, wherein said fusion protein comprises amino acid 40 to amino acid 190 of SEQ ID NO:1. ### Claim 4 (depends on 1) The composition of claim 1, wherein said fusion protein comprises amino acid 35 to amino acid 190 of SEQ ID NO:1. ### Claim 5 (depends on 1) The composition of claim 1, wherein said fusion protein comprises amino acid 30 to amino acid 190 of SEQ ID NO:1. ### Claim 6 (depends on 1) The composition of claim 1, wherein said nucleic acid sequence hybridizes over its full length, after a wash at 50° C. to 60° C. in a buffer containing 0.2×SSC and 0.1% SDS, to the complement of a nucleotide sequence consisting of nucleotide 88 to nucleotide 570 of SEQ ID NO:2. ### Claim 7 (depends on 1) The composition of claim 1, wherein said pharmaceutically acceptable carrier is physiological saline. ### Claim 8 A composition comprising a fusion protein and a pharmaceutically acceptable carrier, wherein said fusion protein comprises: a first domain consisting of a polypeptide that consists of all or part of amino acid 30 to amino acid 311 of SEQ ID NO:1 and includes at least an V-like Ig domain consisting of amino acid 47 to amino acid 150 of SEQ ID NO:1; and at least one additional domain comprising an amino acid sequence that is unrelated to SEQ ID NO:1. ### Claim 9 (depends on 8) The composition of claim 8, wherein said at least one additional domain is all or part of an immunoglobulin heavy chain constant region. ### Claim 10 (depends on 8) The composition of claim 8, wherein said fusion protein comprises amino acid 40 to amino acid 311 of SEQ ID NO: 1. ### Claim 11 (depends on 8) The composition of claim 8, wherein said fusion protein comprises amino acid 35 to amino acid 311 of SEQ ID NO:1. ### Claim 12 (depends on 8) The composition of claim 8, wherein said fusion protein comprises amino acid 30 to amino acid 311 of SEQ ID NO:1. ### Claim 13 (depends on 8) The composition of claim 8, wherein said pharmaceutically acceptable carrier is physiological saline.